메뉴 건너뛰기




Volumn 355, Issue 15, 2006, Pages 1551-1562

Effect of ramipril on the incidence of diabetes

(924)  Bosch, Jackie a,j   Yusuf, S j   Gerstein, H C j   Pogue, J j   Sheridan, P j   Dagenais, G j   Chiasson, J L j   Diaz, R j   Avezum, A j   Lanas, F j   Probstfield, J j   Fodor, G j   Holman, R R j   Anand, S j   Budaj, A j   Conget, I j   Davis, M j   Dinccag, N j   Enjalbert, M j   Escalante, A j   more..


Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMIPRIL; ROSIGLITAZONE;

EID: 33749590988     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa065061     Document Type: Article
Times cited : (683)

References (24)
  • 1
    • 24144472565 scopus 로고    scopus 로고
    • The burden of mortality attributable to diabetes: Realistic estimates for the year 2000
    • Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28:2130-5.
    • (2005) Diabetes Care , vol.28 , pp. 2130-2135
    • Roglic, G.1    Unwin, N.2    Bennett, P.H.3
  • 2
    • 33745400514 scopus 로고    scopus 로고
    • Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study
    • Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36.
    • (2006) Lancet , vol.368 , pp. 29-36
    • Booth, G.L.1    Kapral, M.K.2    Fung, K.3    Tu, J.V.4
  • 3
    • 0035799806 scopus 로고    scopus 로고
    • Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
    • Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
    • (2001) N Engl J Med , vol.344 , pp. 1343-1350
    • Tuomilehto, J.1    Lindstrom, J.2    Eriksson, J.G.3
  • 4
    • 0037034257 scopus 로고    scopus 로고
    • Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
    • Diabetes Prevention Program Research Group
    • Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
    • (2002) N Engl J Med , vol.346 , pp. 393-403
  • 5
    • 0037097039 scopus 로고    scopus 로고
    • Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial
    • Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
    • (2002) Lancet , vol.359 , pp. 2072-2077
    • Chiasson, J.-L.1    Josse, R.G.2    Gomis, R.3    Hanefeld, M.4    Karasik, A.5    Laakso, M.6
  • 7
    • 0035904369 scopus 로고    scopus 로고
    • Ramipril and the development of diabetes
    • Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001;286:1882-5.
    • (2001) JAMA , vol.286 , pp. 1882-1885
    • Yusuf, S.1    Gerstein, H.2    Hoogwerf, B.3
  • 8
    • 33746863179 scopus 로고    scopus 로고
    • Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials
    • Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8.
    • (2006) Lancet , vol.368 , pp. 581-588
    • Dagenais, G.R.1    Pogue, J.2    Fox, K.3    Simoons, M.L.4    Yusuf, S.5
  • 9
    • 5644250670 scopus 로고    scopus 로고
    • Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial
    • The DREAM Trial Investigators
    • The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004;47:1519-27.
    • (2004) Diabetologia , vol.47 , pp. 1519-1527
  • 10
    • 33748748206 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
    • The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
    • The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
    • (2006) Lancet , vol.368 , pp. 1096-1105
  • 11
    • 0032860357 scopus 로고    scopus 로고
    • Worst-rank score analysis with informatively missing observations in clinical trials
    • Lachin JM. Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials 1999;20:408-22.
    • (1999) Control Clin Trials , vol.20 , pp. 408-422
    • Lachin, J.M.1
  • 12
    • 0037432313 scopus 로고    scopus 로고
    • Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies of Left Ventricular Dysfunction (SOLVD)
    • Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003;107:1291-6.
    • (2003) Circulation , vol.107 , pp. 1291-1296
    • Vermes, E.1    Ducharme, A.2    Bourassa, M.G.3
  • 13
    • 19644400972 scopus 로고    scopus 로고
    • Angiotensin-converting-enzyme inhibition in stable coronary artery disease
    • The PEACE Trial Investigators
    • The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
    • (2004) N Engl J Med , vol.351 , pp. 2058-2068
  • 14
    • 0033034404 scopus 로고    scopus 로고
    • Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
    • Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
    • (1999) Lancet , vol.353 , pp. 611-616
    • Hansson, L.1    Lindholm, L.H.2    Niskanen, L.3
  • 15
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. [Errata, JAMA 2003;289:178, 2004;291:2196]
    • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. [Errata, JAMA 2003;289:178, 2004;291:2196.]
    • (2002) JAMA , vol.288 , pp. 2981-2997
  • 16
    • 0037434556 scopus 로고    scopus 로고
    • A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly
    • Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
    • (2003) N Engl J Med , vol.348 , pp. 583-592
    • Wing, L.M.H.1    Reid, C.M.2    Ryan, P.3
  • 17
    • 21844434198 scopus 로고    scopus 로고
    • Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure
    • [Erratum, Circulation 2005;112(7):e292]
    • Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112:48-53. [Erratum, Circulation 2005;112(7):e292.]
    • (2005) Circulation , vol.112 , pp. 48-53
    • Yusuf, S.1    Ostergren, J.B.2    Gerstein, H.C.3
  • 18
    • 0042154108 scopus 로고    scopus 로고
    • Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Prfile in a North of Sweden Efficacy Evaluation (ALPINE study)
    • Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Prfile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-74.
    • (2003) J Hypertens , vol.21 , pp. 1563-1574
    • Lindholm, L.H.1    Persson, M.2    Alaupovic, P.3    Carlberg, B.4    Svensson, A.5    Samuelsson, O.6
  • 19
    • 18544376399 scopus 로고    scopus 로고
    • Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study
    • Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86.
    • (2002) J Hypertens , vol.20 , pp. 1879-1886
    • Lindholm, L.H.1    Ibsen, H.2    Borch-Johnsen, K.3
  • 20
    • 2942635317 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
    • Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
    • (2004) Lancet , vol.363 , pp. 2022-2031
    • Julius, S.1    Kjeldsen, S.E.2    Weber, M.3
  • 21
    • 0032902850 scopus 로고    scopus 로고
    • The relationship between glucose and incident cardiovascular events: A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
    • Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
    • (1999) Diabetes Care , vol.22 , pp. 233-240
    • Coutinho, M.1    Gerstein, H.C.2    Wang, Y.3    Yusuf, S.4
  • 22
    • 0037157596 scopus 로고    scopus 로고
    • Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study
    • Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4.
    • (2002) Lancet , vol.359 , pp. 2140-2144
    • Norhammar, A.1    Tenerz, A.2    Nilsson, G.3
  • 23
    • 33746367481 scopus 로고    scopus 로고
    • Antihypertensive medications and the risk of incident type 2 diabetes
    • Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006;29:1065-70.
    • (2006) Diabetes Care , vol.29 , pp. 1065-1070
    • Taylor, E.N.1    Hu, F.B.2    Curhan, G.C.3
  • 24
    • 3142740224 scopus 로고    scopus 로고
    • Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
    • Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61.
    • (2004) Am Heart J , vol.148 , pp. 52-61
    • Teo, K.1    Yusuf, S.2    Sleight, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.